Which peptides have been studied in immune & infectious disease research?
-
KPVLys-Pro-Val
Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.
PreliminaryNot licensed in the UK -
Thymosin Alpha-1Thymalfasin
Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.
ModerateNot licensed in the UK
Best recorded finding for each peptide in this area
| Peptide | UK status | Finding | Study type | Evidence grade |
|---|---|---|---|---|
| KPV | Not licensed in the UK | PepT1 uptake, cells and mice | Animal | Preliminary |
| Thymosin Alpha-1 | Not licensed in the UK | Sepsis 28-day mortality | Human trial | Moderate |
About this research area
"Immune & Infectious Disease Research" groups peptides studied for immunomodulatory effects and outcomes in infectious or critical-illness contexts, including sepsis, chronic viral hepatitis and immune-marker changes during recovery from acute illness. Evidence in this category spans mechanistic dendritic-cell and Toll-like-receptor research through to systematic reviews and meta-analyses of randomised controlled trials, with reported outcomes that are mixed rather than uniformly positive, including a primary meta-analysis whose result was no longer statistically significant once restricted to higher-quality trial subsets. Inclusion in this category reflects a substantial published immunology and infectious-disease research literature, not a confirmed treatment effect for any condition.
6 sources in the library relate to this area. See them.
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.